Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TMC207 in MDR-TB
NCT01600963Phase 3Withdrawn
- Sponsor
- Johnson & Johnson
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of bedaquiline in Tuberculosis (TB), sponsored by Johnson & Johnson. Planned start Mar 2014; status: withdrawn.
02
Drugs
bedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01600963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01600963.